China has become the world's second largest pharmaceutical consumer market

Release time:


Wu Zhen, deputy director of the State Food and Drug Administration, said on the 12th that after years of development, China has become the world's second largest pharmaceutical consumer market and the largest exporter of raw materials.

At the opening ceremony of the 2017 seminar on drug quality management in developing countries held on the same day, Wu Zhen said that there are nearly 5000 raw material and preparation enterprises in China, and the annual main business income of the pharmaceutical manufacturing industry exceeds 2.5 trillion yuan. Among them, nearly 50 preparation enterprises have passed the certification or inspection in Europe and the United States, and the export volume of pharmaceutical products exceeds 13.5 billion US dollars, This shows that China's pharmaceutical industry has the ability to provide safe and reliable pharmaceutical products for other countries in the world.

In 2015, Chinese female pharmacist Tu Youyou won the Nobel Prize in Physiology or Medicine. Wu Zhen pointed out that China's pharmaceutical industry is contributing to the development of global innovative drugs and playing an active role in the field of global disease prevention and health protection. As a first-line antimalarial drug recommend by the World Health Organization, artemisinin has saved millions of lives around the world, especially in developing countries. This discovery is called "the greatest medical innovation in the second half of the 20th century".

Wu Zhen also pointed out that there are still some problems in China's pharmaceutical economy and drug supervision, such as regional imbalances in drug research and development, production, circulation and use, and regional incoordination in drug supervision. In addition, with the rapid development of science and technology, drugs show diversity and complexity in R & D, production and use.

In order to effectively speed up the speed of drug review and approval and solve the problem of drug registration backlog, the Food and Drug Administration has taken further measures in the reform of the drug review and approval system this year and achieved good results. In this regard, Wu Zhen pointed out that the Food and Drug Administration has redefined the definition and classification of new drugs, clarified the evaluation criteria that generic drugs must be consistent with the quality and efficacy of the original research drugs, and established a drug evaluation system dominated by clinical efficacy. On the basis of technology and quality, focus on the results of drug clinical trials to ensure the clinical efficacy of listed drugs. (Reporter Chen Cong)